Sophia Abene

The study examines how pathogenicity-related gene clusters integrate into Salmonella's genome to affect disease ability.

This updated guidance incorporates new treatment strategies and recommendations based on the latest data on antimicrobial resistance.

A single-dose dengue vaccine that is effective across various age groups and independent of prior dengue exposure is essential.

There is a high potential for ActivePure Medical’s technology to enhance patient safety and reduce healthcare costs by minimizing harmful pathogens in complex healthcare environments.

Results demonstrate high safety and reduced need for oxygen supplementation in patients with COVID-19 viral pneumonia.

Analyzing data from over 4.6 million sinusitis cases, the study emphasizes the need for focused efforts to improve adherence to treatment guidelines and ensure antibiotics are used correctly.

Given that over 50% of women experience at least one urinary tract infection annually and antimicrobial resistance is on the rise, it's essential to evaluate the evidence for potential non-drug interventions.

The prevalence of methicillin-resistant Staphylococcus aureus has surged from 2.58% to 14.79%, highlighting a need for updated treatment strategies.

Providing nirsevimab (Beyfortus) to all newborns and high-risk infants during the 2024-2025 RSV season represents an advancement in protecting infant health.

Increased funding can lead to the development of resources like rapid diagnostic test kits and improve the overall availability of treatment for those in need.

Omadacycline (Nuzyra) maintained its potency over time and did not show a decrease in effectiveness.

HepB-BD is unavailable in 17 countries, and the number of young children receiving the HepB3 shot has dropped by 10 percentage points or more.

New study reveals a marked reduction in HCV infection rates, falling from 23.4% in 2017 to 6% in 2023.

Malaria control efforts can be impacted by indoor nuisance pest management as ineffective control of pests may erode community trust in vector control products.

This week, NYC has revealed high rates of Hepatitis C virus reinfection, SHEA tackles antimicrobial resistance amidst challenges during the COVID-19 pandemic, and more this week from Contagion.

Multimonth dispensing recipients show a notable decrease in discontinuation rates, highlighting its potential to improve long-term treatment adherence and retention in HIV care programs.

New insights might lead to updated treatments focusing on different viral entry routes, influencing COVID-19 and related conditions.

Three studies provide insights into the ongoing COVID-19 pandemic, the prevalence of post-COVID conditions among primary care patients, the effectiveness of nirmatrelvir/ritonavir treatment, and declines in primary care visits.

SHEA supports funding to address antimicrobial resistance in light of heightened challenges during the COVID-19 pandemic.

While the SCORPIO-HR phase 3 trial did not meet its primary endpoint of sustained symptom resolution, ensitrelvir showed promising results in reducing symptom duration and preventing viral rebound.

Despite advances in antiviral treatments, the study reveals that traditional prevention strategies have not curbed reinfection rates among men who have sex with men linked to specific high-risk behaviors.

Paratek Pharmaceuticals has announced results from a Phase 3 study of omadacycline (Nuzyra), demonstrating its non-inferiority to moxifloxacin in treating moderate to severe community-acquired bacterial pneumonia.

Participants using nasal sprays experienced significantly shorter illness durations and reduced antibiotic usage compared to those receiving usual care.

Evaluating nirmatrelvir–ritonavir over 5-10 days for post-exposure prophylaxis revealed no reduction in symptomatic SARS-CoV-2 infections compared to placebo among asymptomatic adults.

This week, the resurgence of leptospirosis in Wyoming, insights on COVID-19 reinfection severity, avian influenza cases in the US, challenges in medical communication amid scientific advancements, recent FDA recalls, and more from Contagion.

With an efficacy rate of 78% and WHO prequalification, the vaccine rollout aims to vaccinate 6.6 million children across 15 African countries by the end of 2024, marking an advancement in public health efforts to combat malaria's impact

A recent report from the CDC highlights how the COVID-19 pandemic has heightened antimicrobial resistance, resulting in a 20% increase in hospital-onset infections caused by key resistant pathogens.

A Salmonella outbreak associated with Raw Farm in Fresno, California, has sickened at least 165 people, marking the largest US outbreak linked to raw milk in the past decade.

The OraQuick HCV self-test aims to improve testing access and help individuals detect the disease affecting an estimated 58 million people worldwide.

Epidemiologist Courtney Tillman, MPH, emphasizes the importance of routine vaccinations and awareness of occupational risks to prevent human infections.